FDA Drug Recalls

Recalls / Class II

Class IID-0399-2025

Product

niCARdipine Hydrochloride Injection, USP, 25 mg/10 mL (2.5 mg/mL), 10 mL Single Dose Vial, Rx Only, American Regent, Inc., Shirley, NY 11967. NDC carton: 0517-0735-10 / NDC Vial: 0517-0735-01]

Brand name
Nicardipine Hydrochloride
Generic name
Nicardipine Hydrochloride
Active ingredient
Nicardipine Hydrochloride
Route
Intravenous
NDC
0517-0735
FDA application
ANDA090534
Affected lot / code info
Lots, expiry: Lot 24086N0C0, 7/31/2025; Lot 24076N0C0, Lot 24090N0C0, 8/31/2025, Lot 25011N0C0, 6/30/2026;

Why it was recalled

Lack of sterility assurance: Product leakage around the vial neck, which could potentially result in a lack of sterility assurance.

Recalling firm

Firm
American Regent, Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
6610 New Albany Rd E, N/A, New Albany, Ohio 43054-8730

Distribution

Quantity
7,249 (cartons of 10 x 10 mL vials)
Distribution pattern
Nationwide in the USA

Timeline

Recall initiated
2025-04-18
FDA classified
2025-05-01
Posted by FDA
2025-05-07
Status
Ongoing

Source: openFDA Drug Enforcement endpoint. Recall record D-0399-2025. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Nicardipine Hydrochloride · FDA Drug Recalls